Cavanaugh Sarah 4

What Happened

• Sarah Cavanaugh, Senior Vice President of Corporate Affairs & Administration at Celldex Therapeutics (CLDX), received a grant of 95,000 derivative securities (option award) on June 25, 2026. The filing records the price as $0.00 per share (award/derivative), indicating a grant of options rather than an immediate cash purchase or sale.

Key Details

• Transaction date: 2026-06-25; filing date: 2026-06-29 (filed within the Form 4 two-business-day window).
• Transaction type/code: A (Award/Grant of derivative securities).
• Amount: 95,000 options; price reported as $0.00 in the filing.
• Vesting: 25% vests on June 25, 2027; the remainder vests quarterly in equal amounts over the subsequent 12 quarters (per footnote).
• Plan: Award made under Celldex’s 2021 Omnibus Equity Incentive Plan.
• Shares owned after transaction: Not specified in the filing.
• No indication of immediate sale, tax withholding, or a 10b5-1 plan in the filing.

Context

• This is a compensation-related option grant (routine for executives) and not an open-market purchase or sale; such awards are common and reflect compensation rather than a direct market sentiment signal. As a derivative award, value and exercise terms beyond the vesting schedule (e.g., exercise price, expiration) are not detailed in this summary and would be in the full plan or award agreement.